RBQM Adoption: Current Use, Overcoming Barriers, And Anticipating ICH E6 (R3)
Steve Young, member of Avoca Quality Consortium, PHUSE Working Group participant, and Tufts survey contributor, discusses the findings of the groups’ joint global research study with CluePoints and Price Waterhouse Cooper (PwC), the implications of the upcoming ICH E6(R3) guidelines, and the future of risk-based clinical trial conduct.
CLINICAL DATA MANAGEMENT & ANALYTICS
How Can Non-Randomized RWE Studies Complement RCTs?
While RWE can provide deep insights into the drug development process, inform regulatory decisions, and supplement clinical research, it does have its limitations. Researchers with the RCT-DUPLICATE Initiative have emerged with key learnings to further inform the industry on the capabilities of RWE.
Capturing EHR Data In Just A Few Clicks
Delve into the details of how this EHR-to-EDC integration platform streamlines data entry efforts at clinical trial sites, simplifying and accelerating the transfer of source data.
New Name, Same Great Experience: Meet Zelta
Formerly Merative Clinical Development, Zelta has more than a decade of logged vision, innovation, and success. Accelerate your clinical trials with unmatched control and confidence today.
CHOOSE YOUR OWN ADVENTURE
You're receiving the Friday edition of the Clinical Leader newsletter, focusing on Clinical Data Management & Analytics and Trial Monitoring. To make changes to your newsletter selections, update your topic preferences.
- Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
- Clinical Trial Technology (Tuesday)
- Decentralized Trials | Trial Management (Wednesday)
- Outsourcing Models | Regulatory & Compliance (Thursday)
- Clinical Data Management & Analytics | Trial Monitoring (Friday)
Learn more about our personalized newsletters here.
|Connect With Clinical Leader:|